

Agonistic CD40 Antibodies

Field of invention

5

The present invention relates to humanized monoclonal agonistic antibodies or antigen-binding fragments thereof that specifically bind to human CD40 receptor and are capable of inducing CD40 signaling independent of Fcγ mediated CD40 receptor crosslinking. The invention also relates to uses of said antibodies and pharmaceutical compositions comprising them.

10

Background

Recent success in cancer immunotherapy has revived the hypothesis that the immune system can control many if not most cancers, in some cases producing durable responses in a way not seen with many small-molecule drugs. Agonistic CD40 monoclonal antibodies (mAb) offer a new therapeutic option which has the potential to generate anticancer immunity by various mechanisms.

20 CD40 is a cell-surface molecule and a member of the tumor necrosis factor (TNF) receptor superfamily. It is expressed broadly on antigen-presenting cells (APC) such as dendritic cells, B cells, and monocytes as well as many nonimmune cells and in a range of tumors.

The natural ligand for CD40 is CD154, which is expressed primarily on the surface of activated T lymphocytes and provides a major component of T-cell "help" for immune responses: Signaling via CD40 on APC mediates, in large part, the capacity of helper T cells to license APC. Ligation of CD40 on DC, for example, induces increased surface expression of costimulatory and MHC molecules, production of proinflammatory cytokines, and enhanced T-cell triggering. CD40 ligation on resting B cells increases antigen-presenting function and proliferation.

30

The consequences of CD40 signaling are multifaceted and depend on the type of cell expressing CD40 and the microenvironment in which the CD40 signal is provided. Like some other members of the TNF receptor family, CD40 signaling is mediated by adapter molecules rather than by inherent signal transduction activity of the CD40 cytoplasmic tail. Downstream kinases are

activated when the receptor is assembled, a multicomponent signaling complex translocates from CD40 to the cytosol and several well-characterized signal transduction pathways are activated.

Antagonizing human CD40 antibodies are known in the prior art. Respective antagonistic
5 antibodies may be silent Fc variants, showing a reduced Fcγ mediated CD40 receptor cross-linking. Respective mutations of the human IgG1 FC region are described in for example US 2018/0118843.

In recently designed immunomodulatory approaches, CD40-targeting agonist monoclonal
10 antibodies (mAbs) are used to enhance the ability of the immune system to recognize and destroy cancer cells. Respective pre-clinical studies have shown that agonistic CD40 mAb can activate APC and promote antitumor T-cell responses and to foster cytotoxic myeloid cells with the potential to control cancer in the absence of T-cell immunity. Thus, agonistic CD40 mAb are fundamentally different from mAb that accomplish immune activation by blocking negative check-point molecules such as CTLA-4 or PD-1.

15

CP-870,893 is the first fully human IgG2 mAb that operates as a potent and selective agonist of CD40. Interestingly, binding of CP-870,893 does not compete with CD154 binding to CD40. In preclinical studies, CP-870,893 has been shown to mediate both immune system-dependent and -
independent effects on tumor cell survival. In the first-in-human study, promising antitumor
20 activity was observed, especially in patients with melanoma. Pharmacodynamically, the administration of CP-870,893 leads to a transient decrease in peripheral blood B cells and to the upregulation of activation markers on APCs.

Thus, agonistic CD40 mAbs represent a promising strategy for novel cancer therapeutics.
25 However, also concerns have been raised in respect to their potential cytotoxic side-effects. Agonistic monoclonal CD40 antibodies stand in prospect of triggering cytokine release syndromes, autoimmune reactions, thromboembolic syndromes (due to the expression of CD40 by platelets and endothelial cells), hyper immune stimulation leading to activation-induced cell death or tolerance, and tumor angiogenesis. These effects may cause untoward toxicity or the promotion
30 of tumor growth. Mechanistically, the ability of agonistic CD40 and other TNF receptor family targeting antibodies to interact with Fcγ receptors has been linked to the occurrence of toxicities in animal studies (Li & Ravetch 2012, Xu et al. 2003, Byrne et al. 2016)

For the strongest agonist tested, CP-870,893, the most common side effect that has been reported is cytokine release syndrome, manifesting as chills, fever, rigors, and other symptoms soon after infusion. Also, several cases of thromboembolic events have been observed with CP-870,893. With Dacetuzumab, noninfectious inflammatory eye disorders have been observed.

5

Therefore, there is a need to provide for agonistic CD40 mABs, that exhibit reduced cellular toxicity, leading to fewer clinical side-effects while maintaining their potency and clinical effectiveness. The agonistic CD40 mABs of the present invention can fulfill this need, allowing for the exploitation of the full immunomodulatory potential of agonistic CD40 antibodies.

10

Summary of invention

The present invention provides for monoclonal antibodies or an antigen-binding fragment thereof that specifically bind to human CD40 receptor and induce CD40 signaling independent of Fcγ mediated CD40 receptor crosslinking. More specifically, the antibodies of the present invention bind to a CD40 epitope that overlaps with the epitope of the CD40 ligand and are capable of activating human APCs. The present invention also provides for compositions comprising said antibodies and uses for the antibodies and compositions in the treatment of a condition or disease, in which the stimulation of the immune system is desired, e.g. in the treatment of patients suffering from cancer.

20

Definitions

25

The term "antibody" encompasses the various forms of antibody structures including, but not being limited to, whole antibodies and antibody fragments as long as it shows the properties according to the invention.

An "antibody fragment" refers to a molecule other than an intact antibody that comprises a portion of an intact antibody that binds the antigen to which the intact antibody binds. Examples of antibody fragments include but are not limited to Fv, Fab, Fab', Fab'-SH, F(ab')₂; diabodies; linear antibodies; single-chain antibody molecules (e.g. scFv); and multi-specific antibodies formed from antibody fragments.

30

The terms "monoclonal antibody" or "monoclonal antibody composition" as used herein refer to a preparation of antibody molecules of a single amino acid composition.

- 5 The term "humanized antibody" or "humanized version of an antibody" refers to antibodies for which both heavy and light chains are humanized as a result of antibody engineering. A humanized chain is typically a chain in which the V-region amino acid sequence has been changed so that, analyzed as a whole, is closer in homology to a human germline sequence than to the germline sequence of the species of origin. Humanization assessment is based on the resulting
10 amino acid sequence and not on the methodology per se.

- The terms "specifically binding, against target, or anti-target antibody ", as used herein, refer to binding of the antibody to the respective antigen (target) or antigen-expressing cell, measured by ELISA, wherein said ELISA preferably comprises coating the respective antigen to a solid support,
15 adding said antibody under conditions to allow the formation of an immune complex with the respective antigen or protein, detecting said immune complex by measuring the Optical Density values (OD) using a secondary antibody binding to an antibody according to the invention and using a peroxidase-mediated color development.

- 20 The term "antigen" according to the invention refers to the antigen used for immunization or a protein comprising said antigen as part of its protein sequence. For example, for immunization a fragment of the extracellular domain of a protein (e.g. the first 20 amino acids) can be used and for detection/assay and the like the extracellular domain of the protein or the full-length protein can be used.

- 25 The term "specifically binding" or "specifically recognized" herein means that an antibody exhibits appreciable affinity for an antigen and, preferably, does not exhibit significant cross-reactivity.

- An antibody that "does not exhibit significant cross-reactivity" is one that will not appreciably
30 bind to an undesirable other protein. Specific binding can be determined according to any art-recognized means for determining such binding, e.g. by competitive binding assays such as ELISA.

An "antibody that binds to the same epitope" as a reference antibody refers to an antibody that blocks binding of the reference antibody to its antigen in a competition assay by 50% or more,

and conversely, the reference antibody blocks binding of the antibody to its antigen in a competition assay by 50% or more.

5 The "variable region (or domain) of an antibody according to the invention" (variable region of a light chain (VL), variable region of a heavy chain (VH)) as used herein denotes each of the pair of light and heavy chain regions which are involved directly in binding the antibody to the antigen. The variable light and heavy chain regions have the same general structure and each region comprises four framework (FR) regions whose sequences are widely conserved, connected by three complementary determining regions, CDRs.

10

The term "antigen-binding portion of an antibody" when used herein refers to the amino acid residues of an antibody which are responsible for antigen-binding. The antigen-binding portion of an antibody comprises preferably amino acid residues from the "complementary determining regions" or "CDRs". The CDR sequences are defined according to Kabat et al, Sequences of
15 Proteins of Immunological Interest, 5th Ed. Public Health Service, National Institutes of Health, Bethesda, Md. (1991). Using this numbering system, the actual linear amino acid sequence may contain fewer or additional amino acids corresponding to a shortening of, or insertion into, a FR or CDR of the variable region. For example, a heavy chain variable region may include a single amino acid insert (residue 52a according to Kabat) after residue 52 of H2 and inserted residues
20 (e.g. residues 82a, 82b, and 82c, etc. according to Kabat) after heavy chain FR residue 82. The Kabat numbering of residues may be determined for a given antibody by alignment at regions of homology of the sequence of the antibody with a "standard" Kabat numbered sequence.

The "constant domains (constant parts)" are not involved directly in binding of an antibody to an
25 antigen, but exhibit e.g. also effector functions. The heavy chain constant region gene fragment that corresponds to human IgG1 is called $\gamma 1$ chain. The heavy chain constant region gene fragment that correspond to human IgG3 is called $\gamma 3$ chain. Human constant γ heavy chains are described in detail by Kabat, E.A. et al., Sequences of Proteins of Immunological Interest, 5th ed., Public Health Service, National Institutes of Health, Bethesda, MD. (1991), and by Brueggemann,
30 M., et al., J. Exp. Med. 166 (1987) 1351-1361; Love, T.W., et al., Methods Enzymol. 178 (1989) 515-527.

The term "Fc region" herein is used to define a C-terminal region of an immunoglobulin heavy chain that contains at least a portion of the constant region. The term includes native sequence Fc regions and variant Fc regions.

5 Unless otherwise specified herein, numbering of amino acid residues in the Fc region or constant region is according to the EU numbering system, also called the EU index, as described in Kabat, et al., Sequences of Proteins of Immunological Interest, 5th Ed. Public Health Service, National Institutes of Health, Bethesda, MD (1991).

10 A "variant Fc region" comprises an amino acid sequence which differs from that of a "native" or "wildtype" sequence Fc region by virtue of at least one "amino acid modification" as herein defined.

The term "Fc-variant" as used herein refers to a polypeptide comprising a modification in the Fc domain. The modification can be an addition, deletion, or substitution. Substitutions can include
15 naturally occurring amino acids and non- naturally occurring amino acids. Variants may comprise non-natural amino acids.

The term "Fc region-containing polypeptide" refers to a polypeptide, such as an antibody, which
20 comprises an Fc region.

The terms "Fc receptor" or "FcR" are used to describe a receptor that binds to the Fc region of an antibody. A FcR which binds an IgG antibody (a gamma receptor) includes receptors of the FcγRI, FcγRII, and FcγRIII subclasses, including allelic variants and alternatively spliced forms of these
25 receptors. FcγRII receptors include FcγRIIA (an "activating receptor") and FcγRIIB (an "inhibiting receptor"), which have similar amino acid sequences that differ primarily in the cytoplasmic domains thereof. Activating receptor FcγRIIA contains an immunoreceptor tyrosine-based activation motif (ITAM) in its cytoplasmic domain. Inhibiting receptor FcγRIIB contains an immunoreceptor tyrosine-based inhibition motif (ITIM) in its cytoplasmic domain, (see review in
30 Daeron, M., Annu. Rev. Immunol. 15 (1997) 203-234). FcRs are reviewed in Ravetch, and Kinet, Annu. Rev. Immunol 9 (1991) 457-492; Capel, et al., Immunomethods 4 (1994) 25-34; and de Haas, et al., J. Lab. Clin. Med. 126 (1995) 330-41. Other FcRs, including those to be identified in the future, are encompassed by the term "FcR" herein. The term also includes the neonatal

receptor, FcRn, which is responsible for the transfer of maternal IgGs to the fetus (Guyer, et al., J. Immunol. 117 (1976) 587 and Kim, et al., J. Immunol. 24 (1994) 249).

By "IgG Fc ligand" as used herein is meant a molecule, preferably a polypeptide, from any
5 organism that binds to the Fc region of an IgG antibody to form an Fc/Fc ligand complex. Fc
ligands include but are not limited to FcγRs, FcRn, Clq, C3, mannan binding lectin, mannose
receptor, staphylococcal protein A, streptococcal protein G, and viral FcγR. Fc ligands also include
Fc receptor homologs (FcRH), which are a family of Fc receptors that are homologous to the FcγRs
(Davis, et al., Immunological Reviews 190 (2002) 123-136, entirely incorporated by reference). Fc
10 ligands may include undiscovered molecules that bind Fc. Particular IgG Fc ligands are FcRn and Fc
gamma receptors. By "Fc ligand" as used herein is meant a molecule, preferably a polypeptide,
from any organism that binds to the Fc region of an antibody to form an Fc/Fc ligand complex.

By "Fc gamma receptor", "FcγR" or "FcγgammaR" as used herein is meant any member of the
15 family of proteins that bind the IgG antibody Fc region and is encoded by an FcγR gene. In humans
this family includes but is not limited to FcγRI (CD64), including isoforms FcγRIA, FcγRIB, and
FcγRIC; FcγRII (CD32), including isoforms FcγRIIA (including allotypes H131 and R131), FcγRIIB
(including FcγRIIB-1 and FcγRIIB-2), and FcγRIIc; and FcγRIII (CD 16), including isoforms FcγRIIIA
(including allotypes V158 and F158) and FcγRIIIb (including allotypes FcγRIIB-NA1 and FcγRIIB-NA2)
20 (Jefferis, et al., Immunol Lett 82(2002)), as well as any undiscovered human FcγRs or FcγR
isoforms or allotypes. An FcγR may be from any organism, including but not limited to humans,
mice, rats, rabbits, and monkeys. Mouse FcγRs include but are not limited to FcγRI (CD64), FcγRII
(CD32), FcγRIII (CD 16), and FcγRIII-2 (CD 16-2), as well as any undiscovered mouse FcγRs or FcγR
isoforms or allotypes.

25

By "FcRn" or "neonatal Fc Receptor" as used herein refers to a protein that binds the IgG antibody
Fc region and is encoded at least in part by an FcRn gene. The FcRn may be from any organism,
including but not limited to humans, mice, rats, rabbits, and monkeys. As is known in the art, the
functional FcRn protein comprises two polypeptides, often referred to as the heavy chain and
30 light chain. The light chain is beta-2-microglobulin and the heavy chain is encoded by the FcRn
gene. Unless otherwise noted herein, FcRn or an FcRn protein refers to the complex of FcRn heavy
chain with beta-2-microglobulin.

"Percent (%) amino acid sequence identity" with respect to a peptide or polypeptide sequence is defined as the percentage of amino acid residues in a candidate sequence that are identical with the amino acid residues in the specific peptide or polypeptide sequence, after aligning the sequences and introducing gaps, if necessary, to achieve the maximum percent sequence identity, and not considering any conservative substitutions as part of the sequence identity. Alignment for purposes of determining percent amino acid sequence identity can be achieved in various ways that are within the skill in the art, for instance, using publicly available computer software such as BLAST, BLAST-2, ALIGN or Megalign (DNASTAR) software.

"Antibody-dependent cell-mediated cytotoxicity" and "ADCC" refer to a cell mediated reaction in which nonspecific cytotoxic cells that express FcRs (e.g. Natural Killer (NK) cells, neutrophils, and macrophages) recognize bound antibody on a target cell and subsequently cause lysis of the target cell. The primary cells for mediating ADCC, NK cells, express FcγRIII only, whereas monocytes express FcγRI, FcγRII and FcγRIII. FcR expression on hematopoietic cells is summarized in Table 3 on page 464 of Ravetch, and Kinet, Annu. Rev. Immunol 9 (1991) 457- 492.

The term "Antibody-dependent cellular phagocytosis" and "ADCP" refer to a process by which antibody-coated cells are internalized, either in whole or in part, by phagocytic immune cells (e.g., macrophages, neutrophils and dendritic cells) that bind to an immunoglobulin Fc region.

The term "antibody effector function(s)" or "effector function" as used herein refers to a function contributed by an Fc effector domain(s) of an IgG (e.g., the Fc region of an immunoglobulin). Such function can be effected by, for example, binding of an Fc effector domain(s) to an Fc receptor on an immune cell with phagocytic or lytic activity or by binding of an Fc effector domain(s) to components of the complement system. Typical effector functions are ADCC, ADCP and CDC.

"C1q" is a polypeptide that includes a binding site for the Fc region of an immunoglobulin. C1q together with two serine proteases, C1r and C1s, forms the complex C1, the first component of the complement dependent cytotoxicity (CDC) pathway.

The "class" of an antibody refers to the type of constant domain or constant region possessed by its heavy chain. There are five major classes of antibodies: IgA, IgD, IgE, IgG, and IgM, and several of these may be further divided into subclasses (isotypes), e.g., IgG₁, IgG₂, IgG₃, IgG₄, IgA₁, and

IgA₂. The heavy chain constant domains that correspond to the different classes of immunoglobulins are called α , δ , ϵ , γ , and μ , respectively.

5 An "effective amount" of an agent, e.g., a pharmaceutical formulation, refers to an amount effective, at dosages and for periods of time necessary, to achieve the desired therapeutic or prophylactic result.

The term "cancer" as used herein may be, for example, lung cancer, non-small cell lung (NSCL) cancer, bronchioloalviolar cell lung cancer, bone cancer, pancreatic cancer, advanced pancreatic carcinoma skin cancer, cancer of the head or neck, cutaneous or intraocular melanoma, uterine cancer, ovarian cancer, rectal cancer, cancer of the anal region, stomach cancer, gastric cancer, colon cancer, breast cancer, uterine cancer, carcinoma of the fallopian tubes, carcinoma of the endometrium, carcinoma of the cervix, carcinoma of the vagina, carcinoma of the vulva, Hodgkin's Disease, cancer of the esophagus, cancer of the small intestine, cancer of the endocrine system, cancer of the thyroid gland, cancer of the parathyroid gland, cancer of the adrenal gland, sarcoma of soft tissue, cancer of the urethra, cancer of the penis, prostate cancer, cancer of the bladder, cancer of the kidney or ureter, renal cell carcinoma, carcinoma of the renal pelvis, mesothelioma, hepatocellular cancer, biliary cancer, neoplasms of the central nervous system (CNS), spinal axis tumors, brain stem glioma, glioblastoma multiforme, astrocytomas, schwannomas, ependymomas, medulloblastomas, meningiomas, squamous cell carcinomas, pituitary adenoma, lymphoma, lymphocytic leukemia, including refractory versions of any of the above cancers, or a combination of one or more of the above cancers.

10
15
20

25 **Detailed description of the invention**

The present invention serves the need for providing agonistic CD40 mABs that exhibit a reduced cellular toxicity, leading to fewer clinical side-effects while their signaling potency and clinical effectiveness is at least maintained, if not increased, compared to agonistic CD40 antibodies of prior art.

30

The antibodies or an antigen-binding fragment of the present invention, provide for these advantageous properties as they are capable of specifically binding to the human CD40 receptor and of inducing CD40 signaling independent of Fc γ mediated CD40 receptor crosslinking.

In preferred embodiments, the antibodies according to the invention are humanized IgG1LALA antibodies, humanized IgG1-type antibodies, having at least two alanine amino acids at positions 234 and 235 of the human Fc1 region. Thus, according to a preferred embodiment, a IgG1LALA
5 comprises the mutation L234A and L235A of the human Fc1 region.

Further preferred is that the antibodies according to invention are recombinant molecules.

It is provided by the present invention that an agonistic monoclonal antibody, or an antigen-
10 binding fragment thereof, is capable of binding to the human CD40 receptor and inducing CD40 signaling independent of Fcγ mediated CD40 receptor crosslinking (see also Example 5, Fig. 6 and text below). Furthermore, an antibody according to the present invention may exhibit reduced or depleted signaling capacity through the human Fcγ receptor when compared to the wildtype IgG Fcγ receptor signaling or to Fcγ signaling of antibodies of prior art.

15

In certain embodiments, the agonistic monoclonal CD40 antibodies of the invention, or antigen-binding fragments thereof, may exhibit a reduced or depleted affinity to human Fcγ receptors compared to the wildtype IgG Fcγ. According to a preferred embodiment, inventive antibodies do not bind to Fcγ receptors - correspondingly the inventive antibodies do not trigger Fcγ mediated
20 CD40 receptor crosslinking.

In a preferred embodiment, the antibodies of the present invention comprise at least amino acid substitutions at L234A and L235A of the human IgG1 Fc region or S228P and L235E of the human IgG4 Fc region.

25

It is further preferred for the present invention that the antibodies bind to a CD40 epitope which overlaps with the CD40L binding site. Figures 3 and 16 demonstrate this epitope overlap for the humanized anti-CD40 IgG1-LALA antibodies tested. Also preferred is that the CD40 antibodies compete with CD40L for binding to the CD40 receptor. In epitope competition assays, the
30 antibodies of the invention therefore compete with CD40L. Such assays are described in Examples 3 and 11 and results of experiments with antibodies of the invention are depicted in Figures 3 and 16. Thus, according to a further preferred embodiment, the inventive antibodies inhibit CD40L binding to the CD40 receptor. Figure 19 demonstrates that the antibodies of the invention do not compete with CP-870,893 for binding to CD40.

Antibodies according to the invention possess a very high binding activity to the CD40 receptor. Therefore, in a cell binding assay as outlined in Example 1, the antibodies according to the invention exhibit a binding activity with an EC50 of at most 49,5 ng/ml. Preferably, the EC50 is less
5 than 25ng/ml, more preferably less than 15 ng/ml, less than 9 ng/ml, 7 ng/ml, 6 ng/ml, 5 ng/ml, 4 ng/ml. Most preferred, the EC50 is 3 ng/ml in a cell binding assay as described in Example 1 and as depicted in Figure 1.

The humanized agonistic anti-CD40 antibodies according to the invention may be characterized by
10 biochemical affinities for soluble human or cynomolgus monkey CD40 trimeric protein (cf. Example 13; Figure 18). The inventive antibodies may show KD values of equal or less than 15,7 nM for human CD40. The inventive antibodies may be cross-reactive with cynomolgus monkey CD40 protein with a KD value equal or less than 10,3 nM.

15 Furthermore, the antibodies of the present invention are capable of inducing cellular NF- κ B signaling with high potency. A summary of experiments (cf. Example 2) is depicted in Figure 2, showing EC50 binding values ranging from 1127 to 6243 ng/ml. The EC50 values demonstrate the great potency of the antibodies to induce NF- κ B signaling.

20 It will also be appreciated that the antibodies of the invention can bind to cynomolgus monkey-CD40. The binding activity of the humanized anti-CD40 IgG1-LALA monoclonal antibodies to cynomolgus monkey (*Macaca fascicularis*) is shown in ELISA experiments using recombinant cynomolgus monkey CD40 recombinant protein (cf. Example 4). The EC50 values shown in Fig. 4
25 indicate a potent binding of the antibodies.

Another characteristic of the antibodies of the present invention is that they can activate human APCs. For example, the antibodies can activate cells selected from the group comprising dendritic cells (DCs), B-cells, monocytes and myeloid cells. Preferably, the antibodies activate DCs.

30 This potent CD40 agonistic activity in activating APCs is not due to Fcy-receptor mediated crosslinking of CD40 proteins (c.f. results of experiments shown in Fig. 5, 6 and 7 and described in Example 5).

As such, in one embodiment, the antibodies of the present invention induce the release of IL-12p40 in a dendritic cell maturation assay as described in Example 5. The results of experiments conducted with the antibodies of the present invention in such assay are shown in Figures 5 to 7.

- 5 According to a further preferred embodiment, the inventive antibodies induce maturation of antigen-presenting cells as determined by IL12p70 release which is at least equal to the release that is induced upon stimulation with the antibody CP-870,893-IgG2 and with a EC50 value of equal or less than 208 ng/ml (Fig. 12 and 14). Furthermore, the inventive antibodies induce maturation of antigen-presenting cells as determined by the induction of CD86 by at least 7.5 fold
10 and with an EC50 of equal or less than 148 ng/ml (Fig. 11 and 13).

- Preferably, the antibodies induce a release of IL12p40 from monocyte derived DCs that is at least equal to the release that is induced upon stimulation with the antibody CP-870,893-IgG2 (cf.
15 Fig.6). As said before, this potential to induce DC maturation is not due to signaling via the Fc receptors. The humanized anti-CD40 IgG1-LALA monoclonal antibodies of the invention potently induce monocyte derived dendritic cell activation in an Fc γ receptor-independent manner (see Example 5 and Figure 6). Figure 6 demonstrates that levels of IL12p40 release induced by CP-870,893 variants correlate with the variants ability to bind Fc receptors (IgG1-LALA < IgG2 < IgG1 <
20 IgG1-V11). Strikingly, stimulation by humanized anti-CD40 IgG1-LALA monoclonal antibodies of the invention resulted in Fc-independent IL12p40 secretion levels which covered and even exceeded the range yielded with the CP-870,893 variants. Thus, the anti-CD40 antibodies of the invention provide potent agonistic activity on primary, monocyte derived dendritic cells without Fc γ -receptor mediated crosslinking of CD40 proteins.

- 25 Furthermore, the antibodies of the present invention are very specific in their activation. They do not induce a general release of inflammatory cytokines, such as TNF-alpha (c.f. Example 6 and Fig. 8).

- 30 Another characteristic of the antibodies of the present invention is the reduced clearance of antibodies from the cell surface. CP-870,893 is known to internalize after binding to the CD40 receptor on cells. Clinical studies showed that CP-870,893 is cleared from the circulation in patients rapidly with an estimated half-life of less than 6 hours reflecting a large CD40 receptor sink in patients which may be caused by cellular internalization (Rüter et al 2010).

Antibodies of the invention are retained at the cell surface under conditions allowing endocytosis and internalization (c.f. Example 7 and Fig. 9). In contrast, CP-870,893 variants are not retained at the cell surface under conditions allowing endocytosis and internalization (Fig. 9).

5

It will be appreciated that the antibodies according to the invention have an indirect (immune-mediated) effect on tumor cell death. Thus, the antibodies exhibit an indirect immune cell-mediated cytotoxic effect on tumor cells.

- 10 In one specific embodiment, the antibodies according to the invention do not result in depletion of immune cells expressing CD40 by mechanisms of ADCC, ADCP or CDC.

Thus, in summary, the inventive antibodies may be further characterized by

- (a) no binding to the Fcγ Receptor;
- 15 (b) having a CD40 cell binding affinity with a EC50 value of equal or less than about 49,5 ng/ml;
- (c) having KD values of equal or less than about 15,7 nM;
- (d) being cross reactive to cynomolgus monkey CD40 with a KD value equal or less than about 10,3 nM;
- (e) inhibiting CD40L by binding to CD40;
- 20 (f) prevent synergistic and additive effects of CD40L-mediated functions;
- (g) inducing maturation of antigen presenting cells as determined by IL12p70 release which is at least equal to the release that is induced upon stimulation with the antibody CP-870,893-IgG2 and with an EC50 value of equal or less than about 208 ng/ml and/or as determined by the induction of CD86 on dendritic cells by at least 7,5-fold and with an
- 25 EC50 of equal or less than about 148 ng/ml; and/or
- (h) reducing the level of CD40 on the cell surface to a lesser extent than CP-870,893.

According to a preferred embodiment, the inventive antibodies are characterized by having at least one, two, three, four, five, six, seven or eight or all of the above properties (a to h).

30

Due to the favorable properties of the antibodies of the invention, they are capable of inhibiting the growth of human tumors.

In certain embodiments, an antibody according to the invention may comprise a VH region selected from the group of VH regions comprising the CDR regions selected from the group consisting of a CDR1H region of SEQ ID NO: 29 + n, a CDR2H region of SEQ ID NO: 43 + n and a CDR3H region of SEQ ID NO: 57 + n, wherein n is a number selected from the group consisting of 0 to 13, and a VL region selected from the group of VL regions comprising CDR regions selected from the group consisting of a CDR1L region of SEQ ID NO: 71 + m, a CDR2L region of SEQ ID NO: 85 + m and a CDR3L region of SEQ ID NO: 99 + m, wherein m is a number selected from the group consisting of 0 to 13, and wherein the CDRs may comprise any one or more amino acid mutations that does not diminish their activity according to the invention.

10

Preferably, the antibody comprises a VH region selected from the group of VH regions comprising the CDR regions selected from the group consisting of a CDR1H region of SEQ ID NO: 29 + n, a CDR2H region of SEQ ID NO: 43 + n and a CDR3H region of SEQ ID NO: 57 + n, wherein n is a number selected from the group consisting of 0 to 13, and a VL region selected from the group of VL regions comprising CDR regions selected from the group consisting of a CDR1L region of SEQ ID NO: 71 + m, a CDR2L region of SEQ ID NO: 85 + m and a CDR3L region of SEQ ID NO: 99 + m, wherein m is a number selected from the group consisting of 0 to 13.

15

In certain embodiments, an antibody according to the invention may comprise a VH region selected from the group of VH regions comprising the CDR regions selected from the group consisting of a CDR1H region of SEQ ID NO: 29 + n, a CDR2H region of SEQ ID NO: 43 + n and a CDR3H region of SEQ ID NO: 57 + n, and a VL region selected from the group of VL regions comprising CDR regions selected from the group consisting of a CDR1L region of SEQ ID NO: 71 + n, a CDR2L region of SEQ ID NO: 85 + n and a CDR3L region of SEQ ID NO: 99 + n, wherein n is a number selected from the group consisting of 0 to 13, and wherein the CDRs may comprise any one or more amino acid mutations that does not diminish their activity according to the invention.

20

25

Preferably, the CDRs have a sequence identity to their respective SEQ ID NOs of at least 91%, preferably 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99%.

30

In another embodiment, the antibodies or antigen-binding fragments according to invention comprise a heavy chain variable (VH) region that is least 60% identical, preferably at least 70%

identical, more preferably at least 80% identical, more preferably at least 85 % identical to a VH region selected from the group consisting of VH regions of SEQ ID NO: 1 to 14.

Preferably, said antibodies comprise a heavy chain variable region (VH) sequence having at least
5 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% sequence identity to an amino acid sequence selected from the group of VH sequences of SEQ ID NO: 1 to 14.

In certain embodiments, a VH sequence having at least 60%, 70%, 80%, 85%, 86%, 87%, 88%, 89%,
10 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identity contains substitutions (e.g., conservative substitutions), insertions, or deletions relative to the reference sequence, whereby the antibody retains the ability to bind specifically according to the invention to the respective antigen.

15 The present invention also encompasses an antibody that comprises a heavy chain variable region (VH) comprising an amino acid sequence selected from the group of SEQ ID NO: 1 to 14.

Preferably, the heavy chain variable region (VH) sequence is SEQ ID NO:1, alternatively SEQ ID NO:2, or SEQ ID NO:3, SEQ ID NO:4, SEQ ID NO:5, SEQ ID NO:6, SEQ ID NO:7, SEQ ID NO:8, SEQ ID
20 NO:9, SEQ ID NO:10, SEQ ID NO:11, SEQ ID NO:12, SEQ ID NO:13, SEQ ID NO:14,

The present invention also relates to an antibody that comprises a light chain variable (VL) region that is least 60% identical, preferably at least 70% identical, more preferably at least 80% identical, more preferably at least 85 % identical to a VL region selected from the group consisting
25 of VL regions of SEQ ID NO: 15 to 28.

Preferably, said antibodies comprise a VL sequence having at least 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% sequence identity to an amino acid sequence selected from the group of VL sequences of SEQ ID NO: 15 to 28.

30

In certain embodiments, a VL sequence having at least 60%, 70%, 80%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identity contains substitutions (e.g., conservative substitutions), insertions, or deletions relative to the reference sequence, whereby

the antibody retains the ability to bind specifically according to the invention to the respective antigen.

The present invention also encompasses an antibody that comprises a light chain variable region
5 (VL) comprising an amino acid sequence selected from the group of SEQ ID NO: 15 to 28.

Preferably, the light chain variable region (VL) sequence is SEQ ID NO:15, alternatively SEQ ID NO:16, or SEQ ID NO:17, SEQ ID NO:18, SEQ ID NO:19, SEQ ID NO:20, SEQ ID NO:21, SEQ ID NO:22, SEQ ID NO:23, SEQ ID NO:24, SEQ ID NO:25, SEQ ID NO:26, SEQ ID NO:27, or SEQ ID
10 NO:28.

In certain embodiments, a total of 1 to 10 amino acids have been substituted, inserted and/or deleted in said VL sequences. In other embodiments, a total of 1 to 10 amino acids have been substituted, inserted and/or deleted in said VH sequences. In certain embodiments, a total of 1 to
15 10 amino acids have been substituted, inserted and/or deleted in each of said VH or VL sequences. Said substitutions, insertions, or deletions may occur in regions outside the CDRs (i.e., in the FRs).

The invention also comprises affinity matured antibodies which can be produced according to
20 methods known in the art. Marks et al. *Bio/Technology* 10:779-783 (1992) describes affinity maturation by VH and VL domain shuffling. Random mutagenesis of CDR and/or framework residues is described by: Barbas et al., *Proc Nat. Acad. Sci, USA* 91: 3809-3813 (1994); Schier et al., *Gene* 169: 147-155 (1995); Yelton et al., *J. Immunol.* 1 55:1994-2004 (1995); Jackson et al., *J. Immunol.* 1 54(7):3310-9 (1995); and Hawkins et al., *J. Mol. Biol.* 226:889-896 (1992) and
25 WO2010/108127.

The present invention also encompasses an antibody that comprises a VH region and a VL region comprising the respective CDR1, CDR2 and CDR3 regions of an antibody selected from the group comprising of the antibodies listed in Fig. 10, i.e. comprising the antibodies MAB-16-0283, MAB-
30 16-0377, MAB-16-0267, MAB-16-0386, MAB-16-0451, MAB-16-0346, MAB-16-0325, MAB-16-0388, MAB-16-0464, MAB-16-0262, MAB-16-0406, MAB-16-0484, MAB-16-0400, MAB-16-0489.

The present invention also encompasses an antibody that comprises the SEQ ID NO.: 1 and 15, or SEQ ID NO.: 2 and 16. An antibody according to the invention may also comprise SEQ ID NO.: 3

and 17, or SEQ ID NO.: 4 and 18, or SEQ ID NO.: 5 and 19., or SEQ ID NO.: 6 and 20., or SEQ ID NO.: 7 and 21., or SEQ ID NO.: 8 and 22, or SEQ ID NO.: 9 and 23, or SEQ ID NO.: 10 and 24, or SEQ ID NO.: 11 and 25, or SEQ ID NO.: 12 and 26. Alternatively, an antibody according to the invention comprises SEQ ID NO.: 13 and 27, or SEQ ID NO.: 14 and 28.

5

In another aspect, the antibodies of the invention are for use in the treatment of patients suffering from cancer.

Said cancer can be one or more of the types of cancer selected from the group comprising
10 pancreas cancer, advanced pancreatic carcinoma lung cancer, non-small cell lung (NSCL) cancer, bronchioloalviolar cell lung cancer, bone cancer, pancreatic cancer, skin cancer, cancer of the head or neck, cutaneous or intraocular melanoma, ovarian cancer, rectal cancer, cancer of the anal region, stomach cancer, gastric cancer, colon cancer, breast cancer, kidney cancer, Hodgkin's lymphoma, liver cancer, Gall bladder cancer, bladder cancer, prostate cancer, thyroid cancer,
15 salivary gland cancer, or uterine cancer.

In certain embodiments, the cancer is a solid tumor.

It is also possible in some embodiments, that the cancer is a CD40 expressing cancer. However,
20 this is not necessary for the effective functioning of the antibodies of the invention.

It will be further appreciated that the antibody of the invention may be used as a sole treatment for cancer in a patient or as part of a combination treatment (which further treatment may be a pharmaceutical cytotoxic or cytostatic agent, radiotherapy, targeted therapy and/or surgery).

25

Thus, the patient may also receive one or more further treatments for cancer, for example pharmaceutical agents (such as cytotoxic or cytostatic agents, targeted therapy), radiotherapy and/or surgery.

30 Thus, in some embodiments, the antibody according to the invention is used in the treatment of cancer in combination with cytotoxic or cytostatic agents, radiotherapy, targeted therapy and/or immunotherapy.

The antibodies of the invention can also be used in the treatment of patients that are insufficiently responding and/or resistant to cytotoxic or cytostatic agents, radiotherapy, targeted therapy and/or immune therapy.

- 5 Said radiotherapy may be selected from the group comprising external beam radiation therapy, contact x-ray brachytherapy, brachytherapy, systemic radioisotope therapy or intraoperative radiotherapy.

10 The cytotoxic or cytostatic anti-cancer agents according to the invention may be from the group comprising taxanes, anthracyclins, alkylating agents, histone deacetylase inhibitors, topoisomerase inhibitors, kinase inhibitors, nucleotide analogs, peptide antibiotics, and platinum-based agents.

15 Preferably the targeted anti-cancer agents are used in targeted therapy and selected from one of the following, or combinations thereof: anti-EGFR compounds such as cetuximab, gefitinib, erlotinib, lapatinib, panitumumab, anti-HER2 compounds such as trastuzumab, ado-trastuzumab emtansine, pertuzumab, VEGF-targeting compounds such as bevacizumab, Aflibercept and Pegaptanib and tyrosine kinase inhibitors such as Sunitinib, Pazopanib, Axitinib, Vandetanib, Cabozantinib and Regorafenib.

20 In case the patients are receiving immune therapy, this can be immune checkpoint inhibition and one or more immune checkpoint inhibitors may be used. The one or more immune checkpoint inhibitors may be selected from the group comprising anti-PD-L1, anti-PD-1, anti-CTLA-4, anti-CD137, anti-LAG-3, anti-TIM-3, anti-OX40, and/or anti-GITR.

25 The antibody according to the invention can also be used in combination with an antibody that specifically binds to human PD-L1, CTLA-4, LAG-3, TIM-3, CD137, OX40, GITR and/or in combination with the drug Nivolumab, Pembrolizumab, Urelumab, Utomilumab, Atezolizumab, Avelumab, Durvalumab, Tremelimumab, Ipilimumab .

30 In some embodiments according to the invention, the antibody is used in the treatment of cancer at a weekly to monthly dosing regimen.

One of the special advantages of this invention is that, due to their mutations in the Fc region, the antibodies exhibit less dose or treatment limiting toxicities, compared to the antibodies of prior art. The antibodies provoke the typical side effects of CD40 antibodies, if at all, only to a very limited extend. Such side effects are conditions selected from the group comprising cytokine
5 release syndrome, thrombosis, cerebral embolism, transaminase elevations, lymphopenia, fatigue, peripheral neuropathy, alopecia, constipation, nausea and neutropenia.

In another aspect, the present invention relates to a pharmaceutical composition comprising a pharmaceutically acceptable carrier and a therapeutically effective amount of the antibody
10 according to the invention.

The pharmaceutical composition according to the invention may be used in the treatment of patients suffering from cancer. Such cancer can be a solid tumor. The cancer can also be selected from the group comprising pancreas cancer, advanced pancreatic carcinoma lung cancer, non-
15 small cell lung (NSCL) cancer, bronchioloalviolar cell lung cancer, bone cancer, pancreatic cancer, skin cancer, cancer of the head or neck, cutaneous or intraocular melanoma, ovarian cancer, rectal cancer, cancer of the anal region, stomach cancer, gastric cancer, colon cancer, breast cancer, kidney cancer, Hodgkin's lymphoma, liver cancer, Gall bladder cancer, bladder cancer, prostate cancer, Thyroid cancer, salivary gland cancer, or uterine cancer.

20 The composition can also be used in the treatment of cancer in combination with chemotherapy, radiotherapy, targeted therapy and/or immunotherapy. Said immunotherapy can be immune checkpoint inhibition.

25 The patients treated with said composition may be insufficiently responding and/or resistant to chemotherapy, radiotherapy, targeted therapy and/or immune therapy.

The pharmaceutical composition according to the invention may also be used in the treatment of cancer in combination with one or more cytotoxic, cytostatic or targeted anti-cancer compounds.

30 It can be used in the treatment of cancer in combination with one or more immune checkpoint inhibitors, wherein said immune checkpoint inhibitors may be selected from the group comprising anti-PD-L1, anti-PD-1, anti-CTLA-4, anti-CD137, anti-LAG-3, anti-TIM-3, anti-OX40, and/or anti-GITR.

The composition can also be used in combination with an antibody that specifically binds to human PD-L1, CTLA-4, LAG-3, TIM-3, CD137, OX40, GITR and/or in combination with the drug Nivolumab, Pembrolizumab, Urelumab, Utomilumab, Atezolizumab, Avelumab, Durvalumab, Tremelimumab, Ipilimumab.

It can also be used in the treatment of cancer at a weekly to monthly dosing regimen.

It will be particularly appreciated by the patients that the antibody and composition according to the invention exhibit any dose or treatment limiting toxicities, if at all, only to a very limited extend, and importantly, to less extend than antibodies and compositions of prior art.

In another aspect, the present invention also relates to methods of treatment, comprising the administration of an effective amount of the antibody according to the invention to individuals in need of. Such individuals may be patients suffering from cancer. Thus, the present invention also relates to methods of treatment of cancer, wherein the cancer may be a solid tumor.

The step of administering to an individual in need thereof may comprise the local administration, for example local administration to a tumor in a patient (for example, intra-tumourally or peritumourally).

As the antibody-based agents of the invention are suitable for use in the treatment of any type of cancer for which CD40 activation may provide a therapeutic benefit, the methods comprising the administration of said antibodies are also suitable for treatment of any type of cancer for which CD40 activation may provide a therapeutic benefit.

For example, the cancer may be selected from the group consisting of: prostate cancer; breast cancer; colorectal cancer; pancreatic cancer; ovarian cancer; lung cancer; cervical cancer; rhabdomyosarcoma; neuroblastoma; multiple myeloma; leukemia, acute lymphoblastic leukemia, melanoma, bladder cancer and glioblastoma.

It will be further appreciated that the methods of treatment according to the invention may comprise the sole administration of the antibody-based agents of the invention to a patient or as part of a combination treatment (which further treatment may be a pharmaceutical cytotoxic or cytostatic agent, radiotherapy, targeted therapy and/or surgery).

In fact, all features and favorable properties of the antibodies of the invention as detailed above, are also reflected and comprised in the methods of treatment and uses of the antibodies according to the invention.

5

Examples

The following examples are used in conjunction with the figures and tables to illustrate the invention.

5

Example 1: Cell binding of anti-CD40 antibodies

To determine the potency of humanized anti-CD40 IgG1-LALA monoclonal antibodies in binding to cell-expressed CD40, HEK-Blue-CD40L™ (InvivoGen) cells were seeded in 25µl DMEM containing 10% FBS at a cell density of 1000 cells/well in a cell-culture treated, clear bottom 384-well plate. Antibodies were added to final concentrations ranging from 1,25 µg/ml to 0,01 ng/ml in 5µl medium. After 24h cells were washed three times with 25µl wash buffer (PBS, 0,05% Tween) before Alexa-Fluor-488-conjugated goat anti-human-IgG (Jackson Laboratories) was added at a concentration of 0,8 µg/ml in 20µl medium. Four hours later, 5µl Hoechst dye in medium was added to a final concentration of 5µg/ml. Fluorescent cell binding signals were measured using a CellInsight automated high content imager (Thermo Fisher Scientific). Fitting curves and EC50 calculation were obtained by using Excel (Microsoft) and XLfit (IDBS). Figure 1 summarizes the EC50 binding values ranging from 3 to 49,5 ng/ml.

Example 2: Induction of cellular NF-κB signaling by anti-CD40 agonistic antibodies

The agonistic activity of humanized anti-CD40 IgG1-LALA monoclonal antibodies was tested by stimulating HEK-Blue-CD40L™ (InvivoGen) cells which harbor an NF-κB inducible Secreted Embryonic Alkaline Phosphatase (SEAP) gene construct. 25000 cells/well in 20µl DMEM containing 10% FBS were seeded in a cell-culture treated, clear bottom 384-well plate and cultured overnight. Antibodies were then added in a volume of 5µl medium to final concentrations ranging from 20 to 0,013 µg/ml. After 6 hours of incubation at 37°C and 5% CO₂, 5µl of medium supernatant of each well were transferred to a white, clear bottom 384-well plate containing 20µl of 2x QUANTI-Blue™ reagent (InvivoGen). After incubation for one hour at 37°C and 5% CO₂, optical density at a wavelength of 620 was measured reflecting NF-κB dependent activation of phosphatase secretion. Fitting curves and EC50 calculation were obtained by using Excel (Microsoft) and XLfit (IDBS). EC50 values in Figure 2 indicate the potency of anti-CD40 antibodies to induce NF-κB signaling in the HEK-Blue-CD40L™ cell line.

Example 3: Competition with CD40L binding

Competition of humanized anti-CD40 IgG1-LALA monoclonal antibodies with CD40L binding to CD40 was tested using an ELISA assay. CD40L was coated to the surface of a 384-well Nunc™ MaxiSorp™ plate in a volume of 25µl PBS and at a concentration of 1µg/ml for one hour at room temperature. Antibodies were pre-incubated at a concentration of 5µg/ml with recombinant CD40 protein at a concentration of 1,7 µg/ml in a total volume of 40µl for 1,5 hours at room temperature in ELISA buffer (PBS, 0.5% BSA, 0.05% Tween). The Nunc™ MaxiSorp™ plate was washed three times with wash buffer (PBS, 0.1% Tween) and blocked for one hour at room temperature with PBS, 2% BSA, 0.05% Tween. After three washes in wash buffer, 25µl of the antibody-CD40 complex were added to the Nunc™ MaxiSorp™ plate wells and incubated for one hour at room temperature. After 3 washes in wash buffer, wells were incubated with 25µl of a 1:2000 dilution of anti-human peroxidase-linked, species specific F(ab)₂ Fragment from goat (AbD Serotec) in ELISA buffer for one hour at room temperature. Wells were washed six times with wash buffer and 30µl/well TMB substrate solution (Invitrogen) were added. After 10 minutes at room temperature, 30µl Stop solution (1M HCl) was added per well and absorbance at 450 and 620 nm wavelength was measured using a Tecan M1000 microplate reader. ELISA signal for samples incubated with CP-870,893 indicate the lack of competition with CD40L, while the humanized anti-CD40 IgG1-LALA monoclonal antibodies according to the invention compete with CD40L binding to CD40 (see Figure 3).

Example 4: Cynomolgus monkey-CD40 binding activity

Binding of humanized anti-CD40 IgG1-LALA monoclonal antibodies to cynomolgus monkey- CD40 protein was tested in a biochemical ELISA. Recombinant cyno-CD40 protein (Acro Biosystems) was incubated in a 384-well Nunc™ MaxiSorp™ plate at a concentration of 0,5 µg/ml in PBS for one hour at room temperature. After washing three times with wash buffer (PBS, 0.1% Tween), plates were blocked with PBS, 2% BSA, 0.05% Tween for one hour at room temperature. Plates were washed again three time with wash buffer and antibodies at concentrations ranging from 500 to 0,03 ng/ml in PBS, 0.5% BSA, 0.05% Tween were incubated for one hour at room temperature. After 3 washes in wash buffer, wells were incubated with 12,5µl of a 1:3000 dilution of anti-human peroxidase-linked, species specific F(ab)₂ Fragment from goat (AbD Serotec) in ELISA buffer for one hour at room temperature. Wells were washed six times with wash buffer and 15µl/well TMB substrate solution (Invitrogen) were added. After 10 minutes at room temperature

15µl Stop solution (1M HCl) were added per well and absorbance at 450 and 620 nm wavelength was measured using a Tecan M1000 microplate reader. Fitting curves and EC50 calculation were obtained by using Excel (Microsoft) and XLfit (IDBS). As shown in Figure 4, most antibodies bind to cyno-CD40 with EC50 values between 8 and 31,8 ng/ml.

5

Example 5: Induction of dendritic cell maturation

- 10 a. Monocyte derived dendritic cells were generated to test the ability of humanized anti-CD40 IgG1-LALA monoclonal antibodies to stimulate maturation of dendritic cells as measured by secretion of the IL12p40 cytokine. Human buffy coat preparations from different donors were used to differentiate dendritic cells from monocytes *in vitro*. Buffy coat received from the Bavarian Red Cross was diluted 1:4 with DPBS and layered on Ficoll-Paque (GE Healthcare) density gradients. After centrifugation, interphase Peripheral Blood Mononuclear Cells (PBMCs) were washed three times with DPBS and monocytes were
- 15 isolated using magnetic CD14 MicroBeads (Miltenyi Biotec) according to manufacturer's instructions. Monocytes were cultured in RPMI-1640 containing 10% FCS, 1xPen/Strep, 1x L-Glutamin, 50 ng/ml recombinant human GM-CSF (R&D Systems) and 10 ng/ml recombinant human IL-4 (R&D Systems) at a cell density of $1,2 \times 10^6$ cells/ml in T-175 cell culture flasks. Every 48 hours, 90% of the medium was replaced with fresh, cytokine
- 20 containing medium. At day five, *in vitro* differentiated, immature dendritic cells (IDCs) were harvested and distributed to a cell culture 96-well plate at a cell density of 10^6 cells/ml in 100µl of the same medium.
- b. In one experiment IDCs were stimulated by the addition of anti-CD40 antibodies at a concentration of 5µg/ml. 48h after stimulation, secreted IL12p40 cytokine was quantified in the medium supernatant using a commercially available ELISA kit (R&D Systems) according to the manufacturer's instructions. Figure 5 shows that humanized anti-CD40 IgG1-LALA monoclonal antibodies stimulated IL12p40 release by monocyte derived dendritic cells to different extents, ranging from less than 1ng/ml to more than 24ng/ml, whereas a non-CD40 binding control IgG1-LALA antibody did not lead to stimulation of detectable levels of
- 25 IL12p40.
- 30 c. The humanized anti-CD40 IgG1-LALA monoclonal antibodies of the invention are not able to bind to Fcγ receptors which are expressed on monocyte derived dendritic cells. In order to compare these antibodies with antibodies harboring different Fcγ receptor binding activities, we constructed reference CP-870,893 anti-CD40 antibodies containing human

- IgG1, IgG1-LALA, IgG2 and IgG1-V11 Fc parts and stimulated monocyte derived dendritic cells with different concentrations of these antibodies. The IgG1-V11 form harbors four mutations (G237D, H268D, P271G, A330R) in the heavy chain Fc part. These mutations have been described to selectively increase the affinity to the Fc γ -receptor RIIb (Mimoto et al. 2013). Figure 6 demonstrates that CP-870,893 variants stimulate IL12p40 release in an Fc-dependent manner (IgG1-LALA < IgG2 < IgG1 < IgG1-V11). Strikingly, stimulation by humanized anti-CD40 IgG1-LALA monoclonal antibodies of the invention resulted in Fc-independent IL12p40 secretion levels which covered and even exceeded the range yielded with the CP-870,893 variants. The anti-CD40 antibodies of the invention thereby provide potent agonistic activity on primary, monocyte derived dendritic cells without Fc γ -receptor mediated crosslinking of CD40 proteins.
- d. In another experiment, the potency of humanized anti-CD40 IgG1-LALA monoclonal antibodies to induce IL12p40 secretion by monocyte derived dendritic cells was determined by stimulation with antibody concentrations ranging from 0,005 to 10 μ g/ml. Figure 7 shows that EC50 values for different antibodies ranged between 380 to 743 ng/ml.

Example 6: TNF-alpha release in a high density PBMC assay

To determine whether humanized anti-CD40 IgG1-LALA monoclonal antibodies induce general release of cytokines in blood cells, PBMCs were stimulated with the antibodies according to the protocol of Römer et al. 2011. PBMCs were isolated as described before and cultured in RPMI-1640 containing 10% human AB serum and 1x non-essential amino acids (NEAA) at a cell density of 1×10^7 cells/ml in a T175 cell culture flask. After two days, cells were harvested and seeded at a density of 1×10^6 cells/ml in triplicates in a 96-well cell culture plate. Antibodies were added at a concentration of 10 μ g/ml and incubated with PBMCs for three days at 37°C, 5% CO₂ and 95% humidity. As a positive control, an OKT-3 antibody (Abcam) was included in the experiments. TNF-alpha release was quantified in the cell culture supernatant using a commercially available human-TNF-alpha ELISA kit (R&D Systems) according to the manufacturer's instructions. Figure 8 shows that the anti-CD40 antibodies of the invention and a non-CD40 binding IgG1-LALA control antibody did not stimulate significant release of TNF-alpha by PBMCs, in contrast to the OKT-3 antibody.

Example 7: Cellular pulse-chase assay

Cell binding and internalization dynamics of anti-CD40 antibodies were analyzed in a pulse-chase assay using HEK-Blue-CD40L™ cells (InvivoGen). 2000 Cells/well were seeded in two black 384-well plate with clear bottom in DMEM medium containing 10% FCS. After overnight culture, the anti-CD40 antibodies of the invention and CP-870,893 Fc-variant antibodies as described above were added to one plate at a concentration of 0,8 µg/ml and incubated for 15 min at 37°C and 5% CO₂. Subsequently, both plates were washed three times with cell wash buffer (PBS 0,05% Tween) and incubated for one hour in culture medium. For the last 15 minutes, antibodies were added to plate 2 at a concentration of 0,8 µg/ml. Both plates were then washed three times with cell wash buffer, placed on ice and incubated with 0,8 µg/ml secondary anti-human Alexa-Fluor-488 coupled antibody (Jackson Laboratories) and 5 µg/ml Hoechst stain (Invitrogen) for 30 minutes on ice. Cell surface fluorescent signals were quantified using a CellInsight high content imager (Thermo Fisher Scientific). Figure 9 shows that CP-870,893 variant antibodies have strongly reduced cell surface signals after one-hour incubation in conditions allowing internalization. In contrast, incubation of many of the anti-CD40 antibodies according to the invention under the same conditions result in only minor reduction of cell surface signals indicating limited internalization rates.

Example 8: Correlation of gene reporter induction and dendritic cell maturation activity of humanized anti-CD40 antibodies

a. Cellular gene reporter (HEK-Blue-CD40L™) and dendritic cell (DC) maturation assays were done as described in examples 2 and 5, respectively. Antibodies were used at 5µg/ml for the DC assay and at concentrations ranging from 13 to 20000 ng/ml in the HEK-Blue-CD40L™ gene reporter assay. Figure 10 compares the maximum induction observed in the gene reporter assay with the IL12p40 cytokine release by DCs after stimulation with 5µg/ml of the antibodies. While all 88 humanized anti-CD40-IgG1-LALA antibodies induce gene reporter expression to similar extents, some antibodies show very high stimulation of IL12p40 release by DCs. HEK-Blue-CD40L™ cells do not express Fcγ receptors. The assay is capturing basic, agonistic activities of CD40 antibodies independent of Fcγ receptor binding. DCs express Fcγ receptors and agonistic activities of anti-CD40 antibodies such as CP-870,893 are dependent on Fcγ receptor binding (Example 5). Nevertheless, while most of the 88 IgG1-LALA antibodies lack strong activation of DCs, a minor fraction can induce very strong activation of DCs without Fcγ receptor mediated crosslinking. Therefore, a highly agonistic anti-CD40 antibody, whose activity on primary dendritic cells is

independent of Fc γ -receptor crosslinking, is a rare case and the identification requires to screen a great number of candidate antibodies with basic agonistic activities.

Example 9: Stimulation of costimulatory receptors and cytokine release on dendritic cells by agonistic anti-CD40 antibodies

- a. To test the activity of humanized, agonistic anti-CD40 IgG1-LALA antibodies in stimulating costimulatory receptor expression and inflammatory cytokine release by DCs, immature, monocyte derived DCs (iDCs) were generated from three independent donors as described in Examples 5. iDCs were treated with the antibodies at a concentration of 2 μ g/ml or CD40L (R&D Systems 6245-CL-050) at 20 μ g/ml for 48h. Stimulated, mature DCs were harvested, stained using fluorophore-labelled antibodies against HLA-DR, CD86, CD80, CD83, CD54 and CD95 (all from Miltenyi Biotech) and analyzed by flow cytometry on a BD FACSVerse device. Figure 11 displays the stimulation of receptor expression as fold of induction over isotype antibody control treatment. The data demonstrates strong induction of costimulatory receptors, in particular CD86. CP-870,893 shows overall lower activity compared to antibodies MAB-16-0262, MAB-16-0451, MAB-16-0464 and MAB-16-0406 of the invention. A further reduction of activity is observed when a CP-870,893 variant containing an IgG1-LALA constant part is used, confirming the Fc γ receptor binding dependency of this antibody.
- b. Figure 12 shows the results of cytokine measurements in the supernatants of DC cultures using a BD human inflammatory cytometric bead array kit (BD #551811) according to manufacturer's instructions. Antibodies MAB-16-0262, MAB-16-0451, MAB-16-0464 and MAB-16-0406 of the invention show very high levels of IL-12-p40 and IL-12p70 release, while other cytokines, e.g. TNF- α , IL-1 β , IL-10 and IL-6 are produced and secreted to a far lesser extent. IL-12p40 and IL12p70 release of DCs treated with CP-870,893 IgG2 and IgG1 variants is significantly lower as compared to the release observed with the antibodies of the invention. In similar experiments in vitro differentiated iDCs from three independent donors were treated with agonistic anti-CD40 antibodies for 48 hours at concentrations ranging from 10000 to 5 ng/ml. Receptor expression and cytokine release was analysed as described above. Fitting curves and EC50 calculation were obtained by using Excel (Microsoft) and XLfit (IDBS). Data presented in figures 13 and 14 exemplify dose dependent effects observed in one donor. Results from two further donors showed qualitatively similar effects. In summary, the potency of humanized anti-CD40 antibodies

of the invention as determined by EC50 values is similar to that of CP-870,893, while the maximal induced effect, in particular on IL-12 cytokine release and coreceptor expression is significantly greater than that of CP-870,893.

5 **Example 10: Stimulation of costimulatory receptors on B-cells by agonistic anti-CD40 antibodies**

10 a. The stimulation of of costimulatory receptors by humanized anti-CD40 IgG1-LALA antibodies was also tested on B-cells. PBMCs from three different donors were isolated from human buffy coat by Ficoll density gradient centrifugation and untouched B-cells were purified by negative magnetic enrichment using a B-cell isolation kit II (Miltenyi Biotech) according to manufacturer's instructions. 2×10^5 B-cells in 100 μ l RPMI-1640 + 10% Human AB Serum were stimulated with antibodies concentration ranging from 500 to 0,2 ng/ml for 48h. Stimulated B-cells were harvested, stained using fluorophore-labelled antibodies against HLA-DR, CD86 and CD80 (all from Miltenyi Biotech) and analyzed by flow cytometry on a BD FACSVerse device. Figure 15 displays the dose dependent stimulation of receptor expression in B-cells of one donor as fold of induction over isotype antibody control treatment. Fitting curves and EC50 calculation were obtained by using Excel (Microsoft) and XLfit (IDBS). The results demonstrate that the antibodies of the invention also stimulate costimulatory receptors on B-cells, however, the level of upregulation is lower than that observed in DCs.

Example 11: Competition of CD40L with anti-CD40 antibody binding to CD40 on cells

25 a. Binding of anti CD40 antibodies of the invention to HEK-Blue-CD40L™ cells in the presence of CD40L was tested to verify whether the antibodies bind to the CD40L binding site of cell surface CD40. HEK-Blue-CD40L™ cells were preincubated with antibodies at their EC90 binding concentration for 30 minutes at 40°C. CD40L containing a mouse-IgG2a Fc-tag (AB Biosciences) was added at concentration ranging from 10000 to 9,8 ng/ml and cells were incubated for 60 minutes at 4°C. Anti-CD40 antibodies and CD40L bound to cell-expressed CD40 were detected using secondary DyLight 405-conjugated anti-mouse IgG and Alexa Fluor 488-conjugated anti-human IgG (Jackson Laboratories) and analyzed using FACSVerse instrument (BD). Figure 16A shows stable binding of anti-CD40 concentrations except for CP-870,893 whose antibody binding signal slightly decreases at

higher CD40L concentrations. CD40L binds to the cells in a dose dependent manner and CP-870,893 does not significantly interfere with CD40L binding (Figure 16B). In contrast, the antibodies of the invention strongly prevent binding of CD40L to cell-expressed CD40, indicating that these antibodies bind to the CD40L binding site of CD40 and block CD40L from binding CD40 (Figure 16B).

Example 12: Induction of FasR (CD95) death receptor expression by agonistic CD40 antibodies in combination with CD40L

- a. To test the interference of CD40L with anti-CD40 antibody mediated effects on cells, Ramos cells were treated with CD40L alone or in combination with agonistic anti- CD40 antibodies. Ramos cells were seeded in 96-well plates in RPMI containing 10% FCS at a cell density of $1,25 \times 10^5$ cells/ml. Antibodies were added to the wells at a concentration of 10 $\mu\text{g/ml}$ and the plate was incubated for 10 minutes at 37°C, 5% CO₂, 95% humidity. CD40L (R&D Systems) was then added to some wells to a final concentration of 10 $\mu\text{g/ml}$ and the plate was incubated over night at 37°C, 5% CO₂, 95% humidity. Cells were washed with DPBS and stained with a FITC-labelled antibody against CD95 (Miltenyi Biotech). Figure 17 shows that CD95 induction by CP-870,893 is strongly increased by the addition of CD40L, while co-treatment of all tested anti-CD40 antibodies of the invention reduce the effect of CD40L. The data indicates, that agonistic anti-CD40 antibodies of the invention which bind the CD40L binding on CD40, prevent synergistic and additive effects by CD40L and therefore allow controlled and safe pharmacology.

Example 13: Affinities of humanized, agonistic anti-CD40 IgG1-LALA antibodies

- a. The biochemical affinities of the antibodies of the invention was determined by surface plasmon resonance measurements. Antibodies were reversibly immobilized to a CM5 sensor chip surface via an anti-human Fc antibody. The kinetics of the interaction of immobilized antibodies with soluble human or cynomolgus monkey CD40 monomeric protein (Acro Biosystems) were analysed on a Biacore T200 SPR instrument. Kinetic data were determined using a Langmuir 1:1 binding model. Figure 18 demonstrates that antibodies MAB-16-0451 and MAB-16-0464 have a K_D of 1,2 and 2,6, whereas MAB-16-0262 and CP-870,893 show K_D values of 15,7 or 8,9, respectively. K_D values generated using cynomolgus monkey CD40 protein demonstrate similar affinities.

Example 14: Competitive binding of anti-CD40 antibodies to CD40

- a. To test whether the humanized, agonistic anti-CD40 antibodies of the invention bind to overlapping regions on the CD40 molecule, a competitive binding ELISA was performed. Antibodies were coated to 384-well Maxisorp plates at a concentration of 625 ng/ml in PBS for 60 minutes followed by a blocking step with PBS, 2% BSA, 0.05% Tween for 70 minutes. All antibodies were incubated separately at a concentration of 10 µg/ml in tubes together with 330 ng/ml HIS-tagged CD40 recombinant protein (Acro Biosystems) and 4 µg/ml peroxidase-coupled anti-HIS detection antibody (Sigma-Aldrich) for 60 minutes in ELISA buffer (PBS, 0.5% BSA, 0.05% Tween). The plate was washed three times with PBS, 0.1% Tween before the antibody/HIS-CD40/anti-HIS-peroxidase mixes were added to the wells of the plate. The plate was incubated for 60 minutes. Wells were washed six times with PBS, 0.1% Tween and 15µl/well TMB substrate solution (Invitrogen) were added. The reaction was stopped with 15µl/well Stop solution (1M HCl) and absorbance at 450 and 620 nm wavelength was measured using a Tecan M1000 microplate reader. Figure 19 demonstrates that the antibodies of the invention do not compete with CP-870,893 for binding to CD40. Each antibody, however, competes with any other antibody of the invention, which demonstrates that these antibodies bind to the same region on CD40. Importantly, since the agonistic activities of the antibodies of the invention cover a broad range (Examples 9 and 10), this shows that the paratopes of the agonistic anti-CD40 antibodies primarily determine the agonistic activity of anti-CD40 antibodies.

Example 15: Antibody-mediated effector function of IgG1-LALA anti CD40 antibodies

- a. To test the potency of a LALA mutation in the constant part of an IgG1 antibody in diminishing antibody-mediated effector function, e.g. ADCC, a Jurkat effector cell reporter cell line based assay (Promega ADCC Bioassay, #G701A) has been applied according to manufacturer's instruction and using HEK-Blue-CD40L™ cells as target cells. 5000 HEK-Blue-CD40L™ cells were seeded per well in a white flat-bottom 384-well assay plate in 25µl DMEM +10% FCS and incubated 20h at 37°C, 5 % CO₂. Medium was replaced with 8µl RPMI medium containing 4% low-IgG FCS before 4000 effector cells per well were added in 8µl of the same medium. Finally, CP-870,893 anti-CD40 antibodies, either containing an IgG1 or an IgG1-LALA Fc-part, were added in 8µl medium at concentrations ranging from

10000 to 0,002 ng/ml. The plate was incubated for 6 h at 37 °C, 5 % CO₂. Effector cell luciferase activity was measured using BioGlo Luciferase assay reagents (Promega) according to the manufacturer's instructions. Luminescence was read using a Tecan M1000 microplate reader. Fold of induction was calculated with the formula RLU (antibody treatment – background) / RLU (vehicle – background). Fitting curves were
5 obtained by using Excel (Microsoft) and XLfit (IDBS). Figure 20 demonstrates that the LALA mutation in IgG1 abrogates Fc-receptor mediated signaling in effector cells.

Example 16: Safety of agonistic anti-CD40 antibody therapy in a humanized mouse model

10

- a. To assess safety, a stem cell humanized mouse model was applied. Nod/Scid/gamma(c)(null) FcRg -/- mice lack mouse activating Fc-receptors. Therefore, Fc-receptor binding of therapeutic antibodies by human immune cells is not compromised by mouse Fc-receptor binding in this model. Mice were irradiated sublethal with 1,4 Gy
15 within the first 24 hours after birth. After 4-6 hours mice were engrafted i.v. with 20000 – 50000 human hematopoietic stem cells isolated from cord blood. 12 weeks after engraftment the presence of human immune cells were validated by flow cytometry of peripheral blood cells. Successfully humanized mice were injected once i.v. with 3 µg/g CP-870,893, MAB-16-0451 or isotype control antibody. Body weight and temperature
20 were measured before treatment and at different time points after antibody injection (Figure 21). The data show a significant reduction in body temperature in 3 of 6 mice treated with CP-870,893 and these mice had to be sacrificed due to severe impairment of body conditions. In contrast, mice treated with MAB-16-0451 did not show significant effects on body temperature, neither there were any other overt signs of impaired body
25 condition. This indicates that highly agonistic anti-CD40-IgG1-LALA antibodies lacking Fc-receptor binding activity, can be applied therapeutically without obvious signs of toxicity whereas toxic effects of the less active, agonistic CP-870,893-IgG2 antibody could be demonstrated in vivo in this model.

Figure legend

Fig.1: Cell binding

The anti-CD40 IgG1-LALA monoclonal antibodies were tested for binding to cell-expressed CD40 antigen on HEK-Blue-CD40L™ cells (InvivoGen). EC50 values demonstrate potent binding of the tested antibodies.

Fig. 2: HEK-Blue EC50 determination in 8-point analysis

The agonistic activity of humanized anti-CD40 IgG1-LALA monoclonal antibodies was tested in a cell-based NF-κB gene reporter assay. HEK-Blue-CD40L™ cells (InvivoGen) were incubated for 24 hours with different concentrations of the antibodies. EC50 values demonstrate the potency of the antibodies to induce NF-κB signaling.

Fig. 3: CD40-Ligand epitope competition

To test whether the humanized anti-CD40 IgG1-LALA monoclonal antibodies bind an epitope overlapping with the CD40L binding site, a CD40L competition ELISA was performed. Different concentrations of anti-CD40 antibodies were pre-incubated with CD40 recombinant protein to form a binding complex. Subsequently, the complex was added to microtiter plates coated with recombinant CD40L. After washing, bound CD40-anti-CD40 complexes were detected using a peroxidase-linked anti-human-F(ab)2 antibody. ELISA signals as for the reference CP-870,893 antibody indicate no competition with CD40L and thus binding to an epitope distinct from the CD40L binding site. The data demonstrates that the tested humanized anti-CD40 IgG1-LALA monoclonal antibodies bind to an epitope overlapping with the CD40L binding site.

Fig. 4: Cynomolgus monkey-CD40 binding activity

Binding activity of the humanized anti-CD40 IgG1-LALA monoclonal antibodies to cynomolgus monkey (*Macaca fascicularis*) was tested in an ELISA using recombinant cynomolgus monkey CD40 recombinant protein (Acro Biosystems). EC50 values indicate potent binding of the antibodies. n.d. = not detectable in the tested concentration range

Fig. 5 a) b): Induction of dendritic cell maturation

To test the agonistic activity of humanized anti-CD40 IgG1-LALA monoclonal antibodies on primary target cells, maturation of monocyte derived, immature dendritic cells was analyzed. Immature dendritic cells, which were differentiated in vitro from monocytes, were incubated for

48h with agonistic anti-CD40 antibodies at a concentration of 5µg/ml. Dendritic cell derived, secreted IL12p40 was subsequently quantified in the medium supernatant by biochemical ELISA.

Fig. 6: Dendritic cell maturation

5 The activity of humanized anti-CD40 IgG1-LALA monoclonal antibodies to stimulate IL12p40 secretion by dendritic cells was determined at different antibody concentration and the activity was compared to CP-870,893 antibodies carrying different Fc-parts (IgG1, IgG1-LALA, IgG2 and IgG1-V11). Antibodies were incubated for 48h with in vitro differentiated immature dendritic cells. IL12p40 release was measured by ELISA.

10

Fig. 7: EC50 determination of anti-CD40 antibodies in dendritic cell maturation

The EC50 values of humanized anti-CD40 IgG1-LALA monoclonal antibodies in dendritic cell mediated IL12p40 secretion was determined by testing antibody concentrations ranging from 10 – 0,005 µg/ml. Antibodies were incubated for 48h with in vitro differentiated immature dendritic cells. IL12p40 release was measured by ELISA.

15

Fig. 8: Cytokine release assay

Humanized anti-CD40 IgG1-LALA monoclonal antibodies were tested in high density PBMC cytokine release assay at 10µg/ml to determine general induction of inflammatory cytokines such as TNF-alpha. The data indicates that in contrast to an anti-CD3 (OKT3) antibody the anti-CD40 antibodies do not induce significant TNF-alpha secretion.

20

Fig. 9: Antibody pulse chase cellular assay

Antibody binding dynamics and internalization was tested in a pulse chase cellular assay. Antibodies were incubated with HEK-Blue-CD40L™ cell cultures for 15 min at a concentration of 0,8 µg/ml. After washing, antibodies were allowed to internalize for 60 min before cells were washed again and remaining cell surface localized anti-CD0 antibody was detected by an Alexa-488 labelled secondary antibody. In conditions not allowing internalization, cells were treated similarly, but antibodies were incubated only for 15 min followed by washing and secondary antibody incubation. The data shows that in conditions allowing internalization, signals from surface localized antibodies are reduced to different extents for the tested humanized anti-CD40 IgG1-LALA monoclonal antibodies. Strong signal reduction is observed for all CP-870,893 antibody isoforms.

30

Fig.10: Correlation of gene reporter induction and dendritic cell maturation activity of humanized anti-CD40 antibodies

88 humanized anti-CD40 IgG1-LALA antibodies were tested for their activity in a HEK-Blue gene reporter and a dendritic cell maturation assay. HEK-Blue gene reporter activity is quantified by OD@655 correlating to induced SEAP secretion, dendritic cell maturation is quantified by IL12p40 release (ELISA).

Fig.11: Stimulation of costimulatory receptors on dendritic cells by agonistic anti-CD40 antibodies

In vitro differentiated immature iDCs were stimulated with agonistic CD40 antibodies, isotype control antibodies or CD40L for 48 hours. Expression of costimulatory receptor molecules was measured by flow cytometry. Mean fluorescence intensities were normalized to isotype control treatments or, in case of CD40L to untreated samples. Induction of expression is expressed as fold of induction (FOI) over control treatment.

Fig.12: Cytokine release by anti-CD40 treated dendritic cells

In vitro differentiated immature iDCs were stimulated with agonistic CD40 antibodies, isotype control antibodies or CD40L for 48 hours. Cytokine release was measured by ELISA (IL-12p40) or by flow cytometry using a BD cytometric bead array.

Fig.13: Dose dependent stimulation of costimulatory receptors on dendritic cells by agonistic anti-CD40 antibodies

In vitro differentiated immature iDCs were stimulated with agonistic CD40 antibodies or isotype control antibodies for 48 hours at concentrations ranging from 10000 to 5 ng/ml. Expression of costimulatory receptor molecules was measured by flow cytometry. Mean fluorescence intensities were normalized to isotype control treatments. Induction of expression is expressed as fold of induction (FOI) over control treatment. Calculated EC50 values are presented in the table.

Fig.14: Dose dependent cytokine release by anti-CD40 treated dendritic cells

In vitro differentiated immature iDCs were stimulated with agonistic CD40 antibodies and isotype control antibodies for 48 hours. Cytokine release was measured by flow cytometry using a BD cytometric bead array.

Fig.15: Dose dependent stimulation of costimulatory receptors on B-cells by agonistic anti-CD40 antibodies

B-cells were stimulated with agonistic CD40 antibodies or isotype control antibodies for 48 hours at concentrations ranging from ranging from 500 to 0,2 ng/ml. Expression of costimulatory receptor molecules was measured by flow cytometry. Mean fluorescence intensities were normalized to isotype control treatments. Induction of expression is expressed as fold of induction (FOI) over control treatment. Calculated EC50 values are presented in the table.

Fig.16: Competition of anti-CD40 antibodies with CD40L binding to cell-expressed CD40

HEK-Blue-CD40L™ cells were preincubated with anti-CD40-IgG1-LALA antibodies at EC90 concentrations before CD40L was added in concentrations ranging from 10000 to 9,8 ng/ml. Anti-CD40 antibodies and CD40L binding to CD40 expressed on the cell surface were detected using different secondary, fluorophore-coupled antibodies.

15

Fig.17: Induction of FasR (CD95) death receptor expression by agonistic CD40 antibodies in combination with CD40L

Ramos B-lymphoma cells were stimulated over night with CD40L alone or in combination with agonistic anti-CD40 antibodies or isotype control antibodies. CD95 expression was quantified by flow cytometry, Upregulation of expression is expressed as fold of induction (FOI) over control treatment.

20

Fig.18: Affinities of humanized, agonistic anti-CD40 IgG1-LALA antibodies

Biochemical affinities were measured by surface plasmon resonance on a Biacore T200 SPR instrument. Kinetic data were determined using a Langmuir 1:1 binding model.

25

Fig.19: Antibody competition on CD40 binding

Binding of a preincubated mix of HIS-tagged CD40 protein and different anti-CD40 antibodies to plates coated with different anti-CD40 antibodies. Consecutive binding of both anti-CD40 antibodies are detected by anti-HIS POD-labelled antibodies.

30

Fig.20: Antibody-mediated effector function of IgG1-LALA anti-CD40 antibodies

Anti-CD40 antibody mediated effector function were analyzed using a Jurkat effector luciferase gene reporter cell line and HEK-Blue-CD40L™ as target cells. IgG1-LALA or IgG1 anti-CD40 antibodies were incubated in doses ranging from 10000 to 0,002 ng/ml with target and effector cells for 6h. The fold of induction of measured luciferase activity indicates anti-CD40 antibody-mediated effector cell activation.

Fig.21: Safety of agonistic anti-CD40 antibody therapy in a humanized mouse model

Nod/Scid/gamma(c)(null) FcRg -/- mice were injected with 3µg/g MAB-16-0451 or CP-870,893 anti-CD40 antibodies on day 0. Temperature was measured before and at different time points after injection. Three mice treated with CP-870,893 which showed striking body temperature reduction had to be sacrificed after 3 days.

Fig.22: Sequences (amino acids in one letter code)

Complete sequences of Variable Regions (VR):

Heavy chain:	VH complete:	SEQ ID NO: 1-14
Light chain:	VL complete:	SEQ ID NO: 15-28

Complementary Determining Regions (CDR):

Heavy Chain:	CDR-H1:	SEQ ID NO: 29-42
	CDR-H2:	SEQ ID NO: 43-56
	CDR-H3:	SEQ ID NO: 57-70
Light Chain:	CDR-L1:	SEQ ID NO: 71-84
	CDR-L2:	SEQ ID NO: 85-98
	CDR-L3:	SEQ ID NO: 99-112

Claims

1. Agonistic monoclonal antibody, or an antigen-binding fragment thereof, that specifically binds to the human CD40 receptor and is capable of inducing CD40 signaling independent of Fcγ mediated CD40 receptor crosslinking.
2. Antibody according to claim 1, wherein the antibody is a humanized IgG1LALA antibody.
3. Antibody according to claim 2, wherein the antibody comprises at least amino acid substitutions at L234A and L235A of the human IgG1 Fc region or S228P and L235E of the human IgG4 Fc region.
4. Antibody according to any of the preceding claims, wherein the antibody binds to an epitope that is overlapping with the CD40L binding site.
5. Antibody according to any of the preceding claims, wherein the antibody activates human APCs.
6. Antibody according to any of the preceding claims, wherein the antibody activates cells selected from the group comprising dendritic cells (DCs), B-cells, monocytes, myeloid cells, and tumor cells.
7. Antibody according to any of the preceding claims, wherein said antibody has an indirect immune cell-mediated cytotoxic effect on tumor cells.
8. Antibody according to any of the preceding claims, which has at least one of the further characteristics
 - (a) no binding to the Fcγ Receptor;
 - (b) having a CD40 cell binding affinity with a EC50 value of equal or less than 49,5 ng/ml;
 - (c) having KD values of equal or less than 15,7 nM;
 - (d) being cross reactive to cynomolgus monkey CD40 with a KD value equal or less than 10,3 nM;
 - (e) inhibiting CD40L by binding to CD40;
 - (f) prevent synergistic and additive effects of CD40L-mediated functions;
 - (g) inducing maturation of antigen presenting cells as determined by IL12p70 release with an EC50 value of equal or less than 208 ng/ml

and/or as determined by the induction of CD86 on dendritic cells by at least 7,5-fold and with an EC50 of equal or less than 148 ng/ml; and/or

(h) reducing the level of CD40 on the cell surface by less than 50%.

9. Antibody according to any of the previous claims, wherein the antibody comprises

- a) a VH region selected from the group of VH regions comprising the CDR regions selected from the group consisting of a CDR1H region of SEQ ID NO: 29 + n, a CDR2H region of SEQ ID NO: 43 + n and a CDR3H region of SEQ ID NO: 57 + n, wherein n is a number selected from the group consisting of 0 to 13, and
- b) a VL region selected from the group of VL regions comprising CDR regions selected from the group consisting of a CDR1L region of SEQ ID NO: 71 + m, a CDR2L region of SEQ ID NO: 85 + m and a CDR3L region of SEQ ID NO: 99 + m, wherein m is a number selected from the group consisting of 0 to 13,

wherein the CDRs may comprise any one or more amino acid mutations that does not diminish their activity according to the invention.

- 10. Antibody or antigen-binding fragment according to any of the previous claims, wherein the antibody comprises a heavy chain variable (VH) region is at least 85 % identical to a VH region selected from the group consisting of VH regions of SEQ ID NO: 1 to 14.
- 11. Antibody according to any of the previous claims, wherein the antibody comprises a light chain variable (VL) region that is at least 85 % identical to a VL region selected from the group consisting of VL regions of SEQ ID NO: 15 to 28.
- 12. Antibody according to any of the previous claims for use in the treatment of patients suffering from cancer.
- 13. Antibody according to claim 12, wherein the cancer is a solid tumor.
- 14. Antibody according to claims 12 or 13, wherein the cancer is selected from the group comprising pancreas cancer, advanced pancreatic carcinoma lung cancer, non-small cell lung (NSCL) cancer, bronchioloalviolar cell lung cancer, bone cancer, pancreatic cancer, skin cancer, cancer of the head or neck, cutaneous or intraocular melanoma, ovarian cancer,

rectal cancer, cancer of the anal region, stomach cancer, gastric cancer, colon cancer, breast cancer, kidney cancer, Hodgkin's lymphoma, liver cancer, Gall bladder cancer, bladder cancer, prostate cancer, Thyroid cancer, salivary gland cancer, or uterine cancer.

15. Antibody according to any of claims - to -14, wherein the antibody is used in the treatment of cancer in combination with cytotoxic or cytostatic agents, radiotherapy, targeted therapy, immunotherapy or surgery.
16. A pharmaceutical composition comprising a pharmaceutically acceptable carrier and a therapeutically effective amount of the antibody according to any of the previous claims.